Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Healthcare: Questcor, Cell Therapeutics, Arena Pharmaceuticals Are Top Movers (STJ, QCOR, CTIC, ARNA, ILNS)
U.S. stocks jumped on Wednesday thanks to strength in the housing sector, as energy stocks threatened to pull the market lower with oil futures tumbling. Earlier in the day, the National Association of Realtors said sales rose 7.8% in August to seasonally adjusted annual rate of 4.82 million, better than the 4.6 million expected by economists. Several healthcare stocks are making notable news at mid day on Wednesday.
St. Jude Medical, Inc. (STJ) stock climbed 0.30% to $43.03 after the shares of STJ was upgraded by analysts at Wells Fargo & Co. from a "market perform" rating to an "outperform" rating in a research report issued to clients and investors today. The company has a 52 week low of $32.13 and a 52 week high of $44.80.
Questcor Pharmaceuticals, Inc. (QCOR) stock plunged 28.84% to $36.30 after Aetna Inc. said it would limit coverage of one of the company`s two marketed drugs, the H.P. Acthar medicine for multiple sclerosis and infant seizures. The company`s second-quarter sales more than doubled to $112.5 million, primarily reflecting expanded use of Acthar.
Additionally, analysts at Oppenheimer raised their price target on shares of Questcor from $59.00 to $69.00 in a research report issued to clients and investors yesterday. The firm currently has an "outperform" rating on the stock.
Cell Therapeutics Inc. (CTIC) stock dropped 2.08% to $2.82. The company regains compliance with the NASDAQ stock exchange`s minimum bid price requirement owing to a one-for-five reverse stock split it executed earlier this month.
Additionally, the company last week said that it has launched its recently approved oncology drug Pixuvri in the EU. Pixuvri was approved by EU regulators in May for the treatment of aggressive B-cell non-Hodgkin lymphoma, or NHL. Approximately 37,000 new cases of aggressive B-cell NHL are diagnosed in the EU every year.
Arena Pharmaceuticals, Inc. (ARNA) shares fell 0.22% to $9.24 after Vivus announced the commercial launch of its weight-loss pill Qsymia Monday, beating rival Arena Pharmaceuticals to first reach the bulging waistbands of obese Americans. Arena and its marketing partner Eisai are expected to launch Belviq early next year.
Intellect Neurosciences, Inc. (ILNS) continued a second day of strong gains , up +17.39%, after it was announced that the firm and MRC Technology have completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein (APP). Additionally, the firms have amended their Service Agreement to reduce Intellect`s cash outlay in exchange for equity. This reflects MRCT`s new strategy of risk sharing on exciting antibody projects.
http://finance.yahoo.com/news/healthcare-questcor-cell-therapeutics-arena-203301787.html
Intellect Neuroscience ILNS breakout!
ILNS breakout!
ILNS
Some useful facts about MRC Technology
The numbers
MRC Technology protects and translates scientific discoveries from the UK Medical Research Council-funded Units and Institutes. The MRC’s budget for this in 2009/2010 was £375 million.
At the start of 2010, total licensing income generated by MRC Technology stood at over £500 million.
The Centre for Therapeutic Discovery has capacity for 8 small molecue and 5 antibody projects per year. This is set to increase to 16 small molecule and 8 antibody projects per year over the next 18 months.
Up to July 2009, DGF has invested over GBP£7 million in 67 early stage research projects with commercial potential.
Over 20 companies are licensed to sell our research reagents.
http://www.mrctechnology.org/about/facts-and-figures
NEWS!!
Intellect Neurosciences and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer's Patients
MRCT Amends Agreement Increasing Its Shared Risk in Development of Humanized Antibody
NEW YORK and LONDON, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and MRC Technology (MRCT), leading specialists in the humanization of antibodies, announced today they have completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein (APP).
Antibodies exist in several isoforms; IgG1 antibodies have the strongest potential to induce inflammation while IgG4 has the lowest potential. The Intellect antibody, called IN-N01, is anticipated to promote the clearance of monomeric, oligomeric and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury and in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy and glaucoma.
Intellect Neurosciences and MRCT also have amended their Service Agreement to reduce Intellect's cash outlay in exchange for equity. This reflects MRCT's new strategy of risk sharing on exciting antibody projects.
"IN-N01 is an important addition to Intellect's diversified preclinical pipeline," commented Daniel G. Chain, PhD, Intellect's Chairman and CEO. "The recent Phase 3 data for bapineuzumab, an IgG1 antibody, despite failing to show improvement in clinical endpoints, demonstrated through the use of biomarkers the drug engaged the amyloid beta target and reduced neurodegeneration indicating both the need for earlier intervention and improved antibody-based therapies. We anticipate IN-N01 will have improved safety, which means that it can be used at higher, more frequent doses that likely will result in clinical efficacy, especially if administered to presymptomatic patients."
IN-N01 could be developed without further modification or empowered by chemically combining the antibody with a small molecule, such as an antioxidant, using Intellect's CONJUMAB(TM) platform technology. The company plans to evaluate IN-N01 in both contexts. Additionally, Intellect plans to test IN-N01 in combination with its tau monoclonal antibodies, TOC1- and TauC3.
"MRCT's collaboration with the team at Intellect Neurosciences applying our unparalleled expertise to this important and timely project will be critical to the development of IN-N01 as a therapeutic antibody and we are confident in its potential success," said Dr. Dave Tapolczay, MRCT's CEO. "We believe Intellect Neurosciences is on track with a promising drug candidate and therefore were pleased to offset their cost of development by sharing in the risk."
About Intellect Neurosciences
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.
For more information, please visit www.intellectns.com.
The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741
About Medical Research Council Technology
MRC Technology (www.mrctechnology.org) is a technology transfer company and charity responsible for adding commercial value to cutting edge scientific discoveries through strategic patent protection, creative licensing of intellectual property (IP), partnered research or further scientific development.
MRC Technology also has small molecule drug discovery and therapeutic antibody facilities, providing lead-stage therapeutic assets to pharmaceutical and biotechnology companies.
MRC Technology's scientists have a proven track record of success in antibody humanization, having humanized more than 50 antibodies including Tysabri(R) and Actemra(R). A further six are in clinical trials (including Vedolizumab) with another two in preclinical studies. For additional information please visit http://www.antibodyengineering.co.uk
The MRC Technology logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14742
Safe Harbor Statement Regarding Forward--Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward--looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward--looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333--128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, which was filed on May 14, 2012.
Contact:
Contact for Intellect Neurosciences:
Jules Abraham
JQA Partners, LLC
917-885-7378
jabraham@jqapartners.com
Contact Information for MRC Technology
Suzy Hargreaves
Marketing & Communications Officer
E-mail: shargreaves@tech.mrc.ac.uk
Phone: +44 (0)20 7391 2798
Media contact
Zyme Communications
Katie Odgaard
E-mail: Katie.odgaard@zymecommunications.com
Phone: +44 (0) 7787 502 947
http://finance.yahoo.com/news/intellect-neurosciences-medical-research-council-133500694.html
Technical Chart Shows Upside on XECHEM INTL INC
Im in shock!XECHEM INTL INC is on the verge of a major change in trend. Check out this site
goo.gl/jvrxA
http://finance.yahoo.com/mbview/threadview/?&bn=2cd4bb83-e6be-3b9b-8b03-8e3350a5d41b&tid=1347979839489-ff7b18a7-8116-418b-8119-7f498540ec49
LOL
GLTA!
InsideBulls.com Profiles The Best Penny Stock Picks: (OTCQX: BRIZF), (OTCQB: CONX), (PINKSHEETS: UNDR), (OTCBB: ILNS)
InsideBulls.com MacReport Media
Your online resource for microcap stock news and information, Insidebulls.com offers a free newsletter featuring some of the best penny stock picks available. Our sole purpose is to find the best penny stock picks and keep you informed with fast moving penny stocks. To receive our amazing penny stock newsletter and alerts go to http://insidebulls.com/
***The following Penny Stocks are active this week:***
Brazil Resources Inc. (OTCQX: BRIZF) is a mineral exploration company with a focus on the acquisition and development of projects in emerging producing gold districts in Brazil and other parts of South America. Currently, the Company is advancing its Montes Aureos property located in the State of Maranhao, Brazil, within the Gurupi gold belt. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
HPIL Holding (OTCQB: HPIL) is a worldwide diversified holding company. HPIL Holding is focused on investing in both private and public companies in differing business sectors. HPIL Holding does not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, acquires various types of business. Also HPIL Holding evaluates the acquisition of intellectual properties and technologies, with a particular interest in the healthcare and environmental quality sectors. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
UnderSea Recovery Corporation (PINKSHEETS: UNDR) engaged in the business of locating and recovering historical shipwrecks,primarily those from the 15th through 19th centuries, andother cultural resources (artifacts and other objects of historical andarchaeological interest) from the world's oceans and large lakes by applyingadvanced technologies in an environmentally and ecologically responsiblemanner. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
Intellect Neurosciences, Inc. (OTCBB: ILNS) is a biopharmaceutical company engaged in the discovery and development of a new breed of innovative disease-modifying therapeutic drugs that are designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious neurodegenerative disorders. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
Subscribe Here - http://www.insidebulls.com/
Disclosure: http://insidebulls.com/ is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit http://insidebulls.com/ for complete risks and disclosures.
CONTACT: INSIDEBULLS.COM INFO@INSIDEBULLS.COM
SOURCE: InsideBulls.com
http://www.equities.com/news/headline-story?dt=2012-09-18&val=489874&cat=hcare
Trending uuup
Can't get shares for 0,011.
I think Ilns will fly soon... 0,015...0,019...
Thank you ElisComing!
Look for ILNS, a David Blech Stock, ... maybe you know where this stock will go...
Hey ElisComing
What does this list stand for?
"List of Issuers with No Outstanding Past-Due Share of the Issuer Accounting Support Fee"
http://pcaobus.org/about/ops/documents/support%20fee/issuers_paid.pdf
Thank you bioguru!
Is there something new about the n-terminus patent and the $2 million milestone payment?
Hey bioguru, when do you expect this big time?
Xechem.com Whois
Registrar
GoDaddy.com, LLC (http://www.godaddy.com)
Whois Server
whois.godaddy.com
Referral URL
http://registrar.godaddy.com
Status
clientDeleteProhibited
clientRenewProhibited
clientTransferProhibited
clientUpdateProhibited
Contact Email
Creation Date
07/13/1998
Updated Date
06/21/2012
Expiration Date
07/12/2013
Registrant
Xechem Inc.
379 Thornall Street
New, Je 08837
Un
Administrative Contact
Swift, Dr. Robert
Xechem Inc.
New, Je 08837
Un
Technical Contact
Swift, Dr. Robert
Xechem Inc.
New, Je 08837
Un
Email:
http://www.ip-adress.com/whois/xechem.com
Xechem India
Dated : 6/6/2012
For changing the status of company from 'Dormant' to 'Active' and allowing any director to sign
MCA e-forms, the dormant company has to file Form 61, followed by filing all the required balance
sheets and annual returns in respect of such company.
1385 01538500 BHUWAN CHANDRA
PANDEY
U74899DL1994PTC056893
XECHEM INDIA PRIVATE
LIMITED
1386 01538514 BHAIRAB DUTT PANDEY U74899DL1994PTC056893
XECHEM INDIA PRIVATE
LIMITED
http://www.mca.gov.in/MCA21/dca/dormant_list/DIRLIST7_01300000_01600000.pdf
No, nothing!
Hey Celtics
Maybe the seller was David Blech:
http://www.secinfo.com/duwTa.t4sn.htm
http://cnsnews.com/news/article/ny-man-admits-illegally-trading-stock-2nd-time
Through this bad promotion all investors will know ILNS - the Alzheimer company now.
David Blech should plead guilty for Xechem fraud!
David Blech should plead guilty for Xechem fraud!
Name and Address Amount and Nature
of Beneficial Holder (1) of Beneficial Ownership Percent of Class (2)
Margery Chassman 83,734,211 (3) 65.8 %
465 W 23rd Street
Suite 12J
New York, New York 10011
Daniel G. Chain 232,905 (4) 0.2 %
Elliot Maza 60,838 (5) 0.05 %
Isaac Onn 10,000 0.008 %
Directors and executive officers as a group (3 persons) 311,743 0.2 %
(1) Except as otherwise noted, the address of record of each of the following individuals is: c/o Intellect Neurosciences, Inc., 45 West 36th St. 3rd Fl., New York, New York 10018.
(2) Percentages based on 66,751,143 shares of common stock issued and outstanding as of June 30, 2011, including as applicable, those shares that may be acquired within 60 days upon the exercise of stock options, warrants and/or the conversion of convertible securities by the relevant stockholder.
(3) Includes 60,600 shares of common stock which may be acquired within 60 days upon the exercise of warrants and/or the conversion of convertible securities by the relevant stockholder .
(4) Includes 139,905 shares of common stock which may be acquired within 60 days upon the exercise of stock options.
(5) Includes 60,838 shares of common stock which may be acquired within 60 days upon the exercise of stock options.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
We describe below any transactions, arrangements or relationships of which we are aware, as of the date of filing of this current report, which occurred since the beginning of the last fiscal year or are currently proposed to which we are or will be a participant (as defined in Item 404 of Regulation S-K); in which the amount involved exceeded or will exceed $120,000; and in which any related person (as defined in Item 404 of Regulation S-K) has or will have a direct or indirect material interest. We include in the description below transactions involving certain of our founders and control persons.
Certain Relationships Involving Margie Chassman and David Blech
Ms. Margie Chassman is one of our founding principal stockholders and is the spouse of Mr. David Blech. Ms. Chassman beneficially owns 65.8% of our common stock, including shares by a trust, for which Ms. Chassman serves as Trustee and of which one of Mr. Blech’s sons is a beneficiary. Ms. Chassman has expressly disclaimed beneficial ownership of certain of the shares that applicable SEC rules deem her to beneficially own. See “Item 12 - Security ownership of certain beneficial owners and management and related stockholder matters.”
FORM 10-K June 30, 2011
NEW YORK (AP) -- A onetime powerful biotechnology financier who was among America's wealthiest before a 1990s criminal fraud conviction pleaded guilty to fresh securities fraud charges Wednesday, admitting that his ban from acting as a securities broker or dealer didn't stop him from plunging illegally back into the world of biotech companies.
David Blech, 56, his head cast downward, pleaded guilty to two counts of securities fraud in U.S. District Court in Manhattan, agreeing not to challenge any sentence he may receive that isn't longer than four years and three months in prison.
The plea came 14 years after he was sentenced to probation for actions he took in response to a large decline in the value of biotechnology stocks in the spring of 1994. His footprint on the universe of biotechnology securities at the time was so large that at least a dozen stocks that his defunct company, D. Blech and Co., had underwritten lost nearly a quarter of their value when his company abruptly closed its doors on Sept. 22, 1994, a day known on Wall Street as "Blech Thursday."
On Wednesday, the Manhattan resident told a magistrate judge that he saw his investments sour again after he invested more than $1 million in late 2006 in a biotech company, Pluristem Therapeutics Inc.
"I was so fascinated with Pluristem and was so convinced that it would be a success that I actually borrowed much of the money I used to help my friends and family to buy Pluristem stock," he said. "By May of 2007, I was heavily in debt, and my financial obligations to my family and to others who had loaned me funds were overwhelming."
He said he began selling much of his stock to pay debts but also bought shares through accounts in the names of family and friends so that he wouldn't damage the value of the company's stock.
"The court should know, however, that I did not make any money on my investment in Pluristem. In fact, I lost several million dollars on my investment in Pluristem over time," he said.
He said he had a similar experience with his investment from 2005 to early 2008 in Intellect Neurosciences Inc. He said he "was desperate for money" in early 2008 and began selling Intellect stock to raise money while he was purchasing the company's shares through accounts in friends' and relatives' names.
"I knew what I was doing was wrong and violated the securities laws," he said.
William Prather, a spokesman for Pluristem, said the company had no immediate comment.
Daniel G. Chain, CEO and chairman of Intellect, said he was disappointed to hear about Blech's plea. "We had no inkling of what was going on as far as manipulating the stock at the time," he said.
Chain called Blech a "true supporter of the company" and said Blech's wife owns more than half of the company's shares, though neither she nor he has any decision-making role and doesn't sit on the board of the New York-based biopharmaceutical company, which works to discover and develop therapeutic drugs to slow, stop or prevent Alzheimer's disease and other serious neurological disorders.
Sentencing was set for Aug. 31, though his attorney, Roland Riopelle, said it was unlikely to occur until later in the year for the father of six children. Blech was freed on $500,000 bail.
Riopelle said Blech on Wednesday was "heavily medicated and has struggled with manic depression his whole life." He called him a "sympathetic figure in a way" who can't seem to overcome his belief that he can have a positive impact on the biotechnology industry.
"Some guys use the stock market like a casino," Riopelle said. "His behavior in the stock market is like a gambler in a casino."
The Securities and Exchange Commission on Wednesday also brought civil charges against Blech and his wife, saying they flouted federal securities laws when they repeatedly made unregistered sales of securities.
"Blech tried to rig the market in favor of his own investments and create a mirage of activity in the stocks of biopharmaceutical companies for which he was soliciting investors," said George S. Canellos, Director of the SEC's New York Regional Office.
The SEC said Blech established more than 50 brokerage accounts in the names of family members, friends, and even a private religious institution.
In 1992, Blech was listed on Forbes magazine's list of the 400 richest Americans with a net worth of more than $300 million. His lawyer said Wednesday that he still has shares left in some companies, but he no longer is worth tens of millions of dollars.
By 2001, Blech told The Seattle Times that he was already planning a comeback.
"I may have one more go at it in me," he said. "This time, I would try to do it in a more measured way, with only one or two biotech companies. I would not try to save the world.
http://finance.yahoo.com/news/ny-man-admits-illegally-trading-230717188.html
David Blech, 56, his head cast downward, pleaded guilty to two counts of securities fraud in U.S. District Court in Manhattan, agreeing not to challenge any sentence he may receive that isn't longer than four years and three months in prison.
The plea came 14 years after he was sentenced to probation for actions he took in response to a large decline in the value of biotechnology stocks in the spring of 1994. His footprint on the universe of biotechnology securities at the time was so large that at least a dozen stocks that his defunct company, D. Blech and Co., had underwritten lost nearly a quarter of their value when his company abruptly closed its doors on Sept. 22, 1994, a day known on Wall Street as "Blech Thursday."
On Wednesday, the Manhattan resident told a magistrate judge that he saw his investments sour again after he invested more than $1 million in late 2006 in a biotech company, Pluristem Therapeutics Inc.
"I was so fascinated with Pluristem and was so convinced that it would be a success that I actually borrowed much of the money I used to help my friends and family to buy Pluristem stock," he said. "By May of 2007, I was heavily in debt, and my financial obligations to my family and to others who had loaned me funds were overwhelming."
He said he began selling much of his stock to pay debts but also bought shares through accounts in the names of family and friends so that he wouldn't damage the value of the company's stock.
"The court should know, however, that I did not make any money on my investment in Pluristem. In fact, I lost several million dollars on my investment in Pluristem over time," he said.
He said he had a similar experience with his investment from 2005 to early 2008 in Intellect Neurosciences Inc. He said he "was desperate for money" in early 2008 and began selling Intellect stock to raise money while he was purchasing the company's shares through accounts in friends' and relatives' names.
"I knew what I was doing was wrong and violated the securities laws," he said.
William Prather, a spokesman for Pluristem, said the company had no immediate comment.
Daniel G. Chain, CEO and chairman of Intellect, said he was disappointed to hear about Blech's plea. "We had no inkling of what was going on as far as manipulating the stock at the time," he said.
Chain called Blech a "true supporter of the company" and said Blech's wife owns more than half of the company's shares, though neither she nor he has any decision-making role and doesn't sit on the board of the New York-based biopharmaceutical company, which works to discover and develop therapeutic drugs to slow, stop or prevent Alzheimer's disease and other serious neurological disorders.
http://finance.yahoo.com/news/ny-man-admits-illegally-trading-230717188.html
RedChip PROMO and MSNBC video today: www.redchip.com/visibility/investor.asp?symbol=CDXC&from=reqreport
RedChip Research Issues Research Update on ChromaDex Corp.
Press Release: RedChip Companies Inc. – 1 hour 10 minutes ago
ORLANDO, Fla., April 25, 2012 (GLOBE NEWSWIRE) -- RedChip Research, a division of RedChip Companies, Inc., today announced it has issued a research update on ChromaDex Corp. (CDXC.OB - News), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries.
To receive a complimentary copy of the RedChip Research Report for CDXC, please visit: http://www.redchip.com/about/aboutmain.asp?rid=407
To learn more about Chromadex Corp., visit http://www.redchip.com/visibility/investor.asp?symbol=CDXC
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Beijing, China; Paris, France; and Seoul, Korea. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(TM), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV(TM), Shareholder Intelligence, Social Media and Blogging Services, Webcasts, and RedChip Radio(TM). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp.
http://finance.yahoo.com/news/redchip-research-issues-research-chromadex-123338412.html
Created a new CDXC forum on germans www.wallstreet-online.de
http://www.wallstreet-online.de/diskussion/1173896-1-10/chromadex-smallcap-a-philipp-frost-billionair-investment
Patent discussion...
A lot of the interest in Network Patent Analysis (NPA) comes from clients who are interested in so called 'white space' between patent clusters. At Ambercite we think that both clusters and white space are important:
clusters show areas of technology investment, which is an important signal,
white space shows the opportunities for new technologies.
But we also know that the white space is often not completely empty, with what we have defined as 'broker patents' acting to bridge different technologies. For example, the figure below which shows the grey broker patents sitting in the middle of three different clusters.
But what if there no broker patents? The figure below is a summary of the patent landscape from our recently published paper on Alzheimers patents - the full NPA landscape map is found here, and is well worth a look.
The structure of this patent landscape plot is very unusual in NPA terms. The patents form into very tight clusters, which in turn fall into two groupings of clusters. This structure can be contrasted to say a more typical NPA map, where there is a central cluster and then a series of clusters around this with significant interactions, such as the smartphone NPA map shown here.
Investigation of the subject matter of the clusters and groupings in the Alzheimer's map suggest that, in very simple terms:
The top grouping ('Amyloid Grouping') are focused on patents claiming drugs trying to prevent the buildup of beta amyloid, a protein which is known to accumulate in plaques found in the brains of Alzheimer's affected patients.
The bottom grouping ('Tau Grouping') is focused on patents claiming drugs focusing on other aspects of brain chemistry, including the important Tau protein, which is present in nerve cells.
The connections between these two groupings were very sparse, comprising just three main patents, as shown in the figure below:
Within the Alzheimer's paper, the highest ranked patent of all in the was US7189819. This patent is thought to protect the drug bapineuzumab, which is undergoing stage III trials at the moment, and which is co-owned by Elan Pharmaceuticals, Johnson & Johnson, and Pfizer. This patent sits right at the centre of the largest cluster 'Peptides and antibodies targeting ß-amyloid' in the top grouping of clusters.
An important paper has just been published on the effect of bapineuzumab on Alzheimer's sufferers, and perhaps surprisingly, it was found that in the trial to have no significant effect on the amount of beta amyloid in the brain. But it was found to reduce the amount of so called 'phosphorylated tau' (p-Tau) in the brain, and this could be an important outcome as p-Tau can be broadly regarded as 'damaged tau', and so may contribute to reduced brain function and other Alzheimer's symptoms. Hence a reduction in p-Tau is possibly a good thing.
And this may not be a totally surprisingly result, as besides building up in Alzheimer patient's brains as plaques, beta amyloid is thought to cause tau to change from normal tau to p-Tau.
But bapineuzumab was supposed to relate to patents found in the Amyloid Grouping, not the Tau Grouping. So did NPA get it wrong?
Well, no. NPA is merely a way of looking at the patent landscape, a lens you could call it. What NPA instead told us is:
all of the companies that have filed patent for bapineuzumab or similar drugs appeared to focused on managing beta amyloid, and
that there was unusual (compared to other technical areas we have looked it) low levels of linkages between the different clusters, and in particular the different groupings. This suggests that there might be opportunities to develop treatments that cut across the different clusters, opportunities that have not been heavily exploited to date. These treatments might be variations of pharmaceuticals targetting different mechanisms, or combinations of drugs to target more than one mechanism at once.
Hence the bapineuzumab p-Tau result has merely confirmed the value of white space analysis, particular when the white space is clearer than normal. Hence the take home lesson is that such clear white space in an NPA landscape should raise the question - what opportunities for new technologies that cross over this white space are going begging?
http://www.ambercite.com/amberblog/tags/tag/bapineuzumab.html
No problem... thinking about Frosts alqa
I know, but Aes-103 (5-Hmf) is a Swift (US) patent.
Registrant:
Xechem Inc.
379 Thornall Street
Edison, New Jersey 08837
United States
Registered through: GoDaddy.com, LLC (http://www.godaddy.com)
Domain Name: XECHEM.COM
Created on: 12-Jul-98
Expires on: 11-Jul-12
Last Updated on: 20-May-11
Administrative Contact:
Swift, Dr. Robert barbarae@xechem.com
Xechem Inc.
379 Thornall Street
Edison, New Jersey 08837
United States
7322050500 Fax -- 7322050504
Technical Contact:
Swift, Dr. Robert barbarae@xechem.com
Xechem Inc.
379 Thornall Street
Edison, New Jersey 08837
United States
7322050500 Fax -- 7322050504